We are live on ! Find out more
FSA

Franklin Street Advisors Portfolio holdings

AUM $1.79B
1-Year Est. Return 28.1%
This Fund
S&P 500
This Quarter Est. Return
+1.27%
1 Year Est. Return
+28.1%
3 Year Est. Return
+112.88%
5 Year Est. Return
+150.28%
10 Year Est. Return
+636.48%
AUM
$667M
AUM Growth
-$1.53M
Cap. Flow
-$63.8K
Cap. Flow %
-0.01%
Top 10 Hldgs %
30.54%
Holding
189
New
11
Increased
58
Reduced
44
Closed
12

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$7.98M
2
D icon
Dominion Energy
D
+$7.78M
3
CAT icon
Caterpillar
CAT
+$6.31M
4
CVS icon
CVS Health
CVS
+$1.77M
5
VFC icon
VF Corp
VFC
+$1.71M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.29M
2
SO icon
Southern Company
SO
+$6.41M
3
HSY icon
Hershey
HSY
+$5.71M
4
LYB icon
LyondellBasell Industries
LYB
+$4.2M
5
BFH icon
Bread Financial
BFH
+$3.97M

Sector Composition

Rank Sector Weight
1 Financials 17.92%
2 Healthcare 17.91%
3 Technology 15.93%
4 Consumer Discretionary 12.97%
5 Industrials 8.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MAT icon
151
Mattel
MAT
$4.32B
$197K 0.03%
15,000
– –
PRQR icon
152
ProQR Therapeutics
PRQR
$241M
$185K 0.03%
+60,000
New +$193K
FPRX
153
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$172K 0.03%
10,000
-15,000
-60% -$293K
ABEO icon
154
Abeona Therapeutics
ABEO
$364M
$158K 0.02%
+440
New +$163K
ARLZ
155
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$145K 0.02%
96,429
– –
MLNT
156
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$97K 0.01%
2,610
+28
+1% +$1.84K
GPM
157
DELISTED
Guggenheim Enhanced Equity Income Fund
GPM
$96K 0.01%
+11,474
New +$102K
NVLN
158
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$91K 0.01%
26,000
– –
RIGL icon
159
Rigel Pharmaceuticals
RIGL
$693M
$71K 0.01%
2,000
– –
TYME
160
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$69K 0.01%
31,000
– –
PDLI
161
DELISTED
PDL BioPharma, Inc.
PDLI
$59K 0.01%
20,000
– –
TOVX icon
162
Theriva Biologics
TOVX
$10.2M
$40K 0.01%
14
– –
FCSC
163
DELISTED
Fibrocell Science Inc.
FCSC
$10K ﹤0.01%
3,333
– –
BRK.A icon
164
Berkshire Hathaway Class A
BRK.A
$1.1T
– –
-2
Closed -$595K
BWA icon
165
BorgWarner
BWA
$13B
– –
-51,785
Closed -$2.33M
FNB icon
166
FNB Corp
FNB
$6.83B
– –
-10,027
Closed -$139K
LYB icon
167
LyondellBasell Industries
LYB
$19.6B
– –
-38,079
Closed -$4.2M
SNA icon
168
Snap-on
SNA
$21.2B
– –
-14,920
Closed -$2.6M
TRMB icon
169
Trimble
TRMB
$13.5B
– –
-84,035
Closed -$3.42M
TXN icon
170
Texas Instruments
TXN
$246B
– –
-3,156
Closed -$330K
UPS icon
171
United Parcel Service
UPS
$90.8B
– –
-2,099
Closed -$250K
WMB icon
172
Williams Companies
WMB
$86.1B
– –
-8,000
Closed -$244K
WMT icon
173
Walmart Inc
WMT
$881B
– –
-6,801
Closed -$224K
SCPX
174
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
0
– -$8K
DISCK
175
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
– –
-18,830
Closed -$399K
4 5 6
7
8

Similar funds

CIM
Cambria Investment Management Manhattan Beach, California $1.79B AUM 28.1% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return
KPM
Kinetic Partners Management Miami, Florida $1.79B AUM 57.3% 1-Year Est. Return
BFG
Berger Financial Group Plymouth, Minnesota $1.79B AUM 15.72% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EFS
Essex Financial Services Essex, Connecticut $1.78B AUM 23.37% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $1.8B AUM 7.28% 1-Year Est. Return
OAM
Ostrum Asset Management Paris, France $1.78B AUM 27.8% 1-Year Est. Return

Franklin Street Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Franklin Street Advisors held 189 positions worth $667M, down 0.23% from $668M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Franklin Street Advisors's Q1 2018 filing shows 11 new, 58 increased, 44 reduced and 12 closed positions. Its largest new stake was Celgene Corp: 15,200 shares worth $1.36M. The largest sale was Merck, an estimated $7.29M.

By sector, the portfolio is most concentrated in Financials at 18% of assets, down from 18% a quarter earlier, followed by Healthcare and Technology.

  • Franklin Street Advisors's largest Q1 2018 buy was Celgene Corp: 15,200 shares worth $1.36M.
  • Franklin Street Advisors added most to Bristol-Myers Squibb in Q1 2018, an estimated $7.98M increase.
  • Franklin Street Advisors's biggest Q1 2018 reduction was Merck, cutting an estimated $7.29M.
  • Franklin Street Advisors fully exited LyondellBasell Industries in Q1 2018, selling an estimated $4.2M.
  • Franklin Street Advisors's ten largest holdings make up 31% of its $667M portfolio in Q1 2018.
  • Franklin Street Advisors opened 11 new positions and closed 12 in Q1 2018.
  • Franklin Street Advisors's portfolio value fell 0.23% quarter-over-quarter to $667M.

Based on Franklin Street Advisors's 13F filing for Q1 2018, filed 11 Apr 2018.